Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Mirati Therapeutics, Inc. is a targeted oncology company developing a pipeline of therapeutics for precisely defined patient populations. The Mirati team is using a blueprint proven by their prior work for developing potential breakthrough therapies with accelerated development paths.
Website: mirati.com



Growth: Good revenue growth rate >200%, there is acceleration compared to average historical growth rates 95.0%. The revenue growth dynamics is moderately stable

Profitability: LTM EBITDA margin is negative, -2 007.9%. On average the margin is decreasing steadily. Gross margin is high, +84.5%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 100% of quarters (showing a gain of +$0.24 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -28.8% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 111.2% higher than minimum and 5.9% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -89.5x by EV / Sales multiple

Key Financials (Download financials)

Ticker: MRTX
Share price, USD:  (0.0%)58.7
year average price 58.70  


year start price 58.70 2025-02-08

max close price 58.70 2025-02-08

min close price 58.70 2025-02-08

current price 58.70 2026-02-07
Common stocks: 56 219 000

Dividend Yield:  0.0%
EV / Sales: 81.4x
Margin (EBITDA LTM / Revenue): -2 007.9%
Fundamental value created in LTM:
Market Cap ($m): 3 300
Net Debt ($m): -208
EV (Enterprise Value): 3 092
Price to Book: 3.5x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-04-05Finbold

How this insider trader nailed every single stock trade

2024-01-11Zacks Investment Research

Mirati (MRTX) Gets EU Nod for Krazati in KRAS-Mutated NSCLC

2023-12-06Zacks Investment Research

Mirati (MRTX) Up 1.1% Since Last Earnings Report: Can It Continue?

2023-11-10Reuters

Mirati's lung cancer drug gets EU's regulatory backing

2023-11-07Zacks Investment Research

Mirati's (MRTX) Q3 Loss Narrows, Sales Miss Expectations

2023-10-09Schaeffers Research

Analysts Target Biotech Name on Buyout Buzz

2023-10-08Reuters

Bristol-Myers Squibb to acquire Mirati in a $4.8 billion deal

2023-10-06Zacks Investment Research

Mirati (MRTX) Surges 45% as Sanofi Reportedly Eyes Buyout

2023-09-22Zacks Investment Research

Mirati (MRTX) Soars 12.3%: Is Further Upside Left in the Stock?

2023-08-09Zacks Investment Research

Mirati (MRTX) Q2 Earnings Beat, Stock Up on Solid Krazati Sales
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4 2019 q4 2018 q4
date 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31 2019-12-31 2018-12-31
symbol MRTX MRTX MRTX MRTX MRTX MRTX MRTX MRTX MRTX
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2023-11-06 2023-08-08 2023-05-09 2022-11-08
acceptedDate 2023-11-06 07:08:36 2023-08-08 16:02:56 2023-05-09 16:22:07 2023-02-28 16:26:14 2022-11-08 16:32:24 2022-02-28 16:20:36 2021-02-25 16:37:11 2020-02-26 16:14:04 2019-02-28 16:53:44
calendarYear 2023 2023 2023 2022
period Q3 Q2 Q1 FY Q3 FY FY FY FY
revenue 16M 14M 7M 12M 5M 72M 13M 3M 13M
costOfRevenue 2M 1M 817 000 600 000 0 2M 299M 183M 94M
grossProfit 14M 12M 6M 12M 5M -437M -286M -180M -81M
grossProfitRatio 0.845 0.906 0.886 1
researchAndDevelopmentExpenses 115M 124M 127M 532M 131M 509M 299M 183M 94M
generalAndAdministrativeExpenses 0 0 0 0 61M 137M 83M 43M 22M
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 72M 75M 73M 240M 61M 137M 83M 43M 22M
otherExpenses 259 000 258 000 9M 0 0 -5M 11M 9M 4M
operatingExpenses 187M 200M 200M 771M 192M 645M 383M 34M 116M
costAndExpenses 188M 201M 201M 772M 192M 645M 383M 225M 116M
interestIncome 0 0 0 0 0 0 0 0 0
interestExpense 0 0 -3M 0 -13M 0 0 0 0
depreciationAndAmortization 1M 1M 1M 3M 716 000 2M 641 000 249 000 175 000
ebitda -171M -186M -194M -757M -186M -571M -369M -222M -103M
ebitdaratio -10.423 -13.598 -27.044 -34.198
operatingIncome -172M -187M -194M -760M -186M -573M -369M -222M -103M
operatingIncomeRatio -10.491 -13.679 -27.044 -34.329
totalOtherIncomeExpensesNet 10M 10M 9M 19M 13M -5M 11M 9M 4M
incomeBeforeTax -162M -177M -185M -740M -173M -578M -358M -213M -98M
incomeBeforeTaxRatio -9.872 -12.923 -25.755 -31.911
incomeTaxExpense 0 0 -9M 508 000 254 000 3M -511 000 -659 000 0
netIncome -162M -177M -175M -741M -174M -582M -358M -213M -98M
netIncomeRatio -9.872 -12.923 -24.466 -31.957
eps -2.49 -3.04 -3.02 -13.18 -3.09 -11.21 -7.96 -5.69 -3.19
epsdiluted -2.49 -3.04 -3.02 -3.09
weightedAverageShsOut 65M 58M 58M 56M 56M 52M 45M 37M 31M
weightedAverageShsOutDil 65M 58M 58M 56M 56M 52M 45M 37M 31M
link Link Link Link Link
finalLink Link Link Link Link
filingDate 2023-02-28 2022-02-28 2021-02-25 2020-02-26 2019-02-28
fiscalYear 2022 2021 2020 2019 2018
netInterestIncome 0 0 0 0 0
ebit -758M -573M -369M -222M -103M
nonOperatingIncomeExcludingInterest -1M 0 0 0 0
netIncomeFromContinuingOperations -741M -582M -357M -213M -98M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 -511 000 -659 000 0
netIncomeDeductions 0 0 -511 000 -659 000 0
bottomLineNetIncome -741M -582M -357M -213M -98M
epsDiluted -13.18 -11.21 -7.96 -5.69 -3.19

Balance Sheet Statement

Property 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4 2019 q4 2018 q4
date 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31 2019-12-31 2018-12-31
symbol MRTX MRTX MRTX MRTX MRTX MRTX MRTX MRTX MRTX
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2023-11-06 2023-08-08 2023-05-09 2022-11-08
acceptedDate 2023-11-06 07:08:36 2023-08-08 16:02:56 2023-05-09 16:22:07 2023-02-28 16:26:14 2022-11-08 16:32:24 2022-02-28 16:20:36 2021-02-25 16:37:11 2020-02-26 16:14:04 2019-02-28 16:53:44
calendarYear 2023 2023 2023 2022
period Q3 Q2 Q1 FY Q3 FY FY FY FY
cashAndCashEquivalents 259M 130M 242M 235M 299M 413M 1 390M 415M 223M
shortTermInvestments 718M 650M 660M 849M 902M 1 078M 0 0 0
cashAndShortTermInvestments 976M 779M 902M 1 084M 1 201M 1 491M 1 390M 415M 223M
netReceivables 20M 16M 6M 865 000 2M 0 0 2M 768 000
inventory 20M 9M 4M 3M 0 -3M -2M -2M -768 000
otherCurrentAssets 19M 15M 27M 21M 23M 17M 14M 9M 4M
totalCurrentAssets 1 036M 819M 939M 1 109M 1 226M 1 508M 1 404M 424M 227M
propertyPlantEquipmentNet 51M 52M 53M 54M 54M 54M 48M 2M 473 000
goodwill 0 0 0 0 0 0 0 0 0
intangibleAssets 14M 14M 15M 15M 0 0 0 0 0
goodwillAndIntangibleAssets 14M 14M 15M 15M 0 0 0 0 0
longTermInvestments 4M 5M 3M 3M 2M 8M 16M 0 0
taxAssets 24M 24M 0 0 0 0 0 0 0
otherNonCurrentAssets 620 000 620 000 23M 22M 21M 19M 9M 6M 1M
totalNonCurrentAssets 94M 96M 94M 94M 77M 81M 72M 8M 2M
otherAssets 0 0 0 0 0 0 0 0 0
totalAssets 1 130M 915M 1 034M 1 203M 1 303M 1 589M 1 476M 432M 228M
accountPayables 38M 33M 22M 39M 19M 35M 18M 48M 26M
shortTermDebt 8M 8M 8M 8M 7M 0 0 0 0
taxPayables 0 0 0 0 0 0 0 0 0
deferredRevenue -8M -8M 0 0 0 -1M 0 824 000 371 000
otherCurrentLiabilities 91M 100M 94M 113M 100M 108M 53M 0 0
totalCurrentLiabilities 137M 140M 125M 159M 127M 144M 71M 49M 26M
longTermDebt 0 0 43M 0 44M 0 0 0 0
deferredRevenueNonCurrent 0 0 0 0 0 0 0 999 000 732 000
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 46M 46M 3M 47M 20M 48M 44M 0 0
totalNonCurrentLiabilities 46M 46M 47M 47M 47M 48M 44M 999 000 732 000
otherLiabilities 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 0 0 43M 0 51M 0 0 0 0
totalLiabilities 183M 186M 171M 206M 174M 192M 115M 50M 27M
preferredStock 0 0 0 0 0 0 0 0 0
commonStock 70 000 58 000 58 000 58 000 58 000 55 000 50 000 40 000 33 000
retainedEarnings -2 976M -2 814M -2 637M -2 453M -2 250M -1 712M -1 130M -772M -559M
accumulatedOtherComprehensiveIncomeLoss -2M -2M -2M -4M -6M 9M 10M 10M 9M
othertotalStockholdersEquity 3 924M 3 545M 3 502M 3 386M
totalStockholdersEquity 946M 729M 863M 997M 1 129M 1 397M 1 361M 382M 202M
totalEquity 946M 729M 863M 997M 1 129M 1 397M 1 361M 382M 202M
totalLiabilitiesAndStockholdersEquity 1 130M 915M 1 034M 1 303M
minorityInterest 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 1 130M 915M 1 034M 1 203M 1 303M 1 589M 1 476M 432M 228M
totalInvestments 718M 654M 660M 849M 904M 1 086M 16M 0 0
totalDebt 50M 51M 43M 52M 51M 46M 42M 0 0
netDebt -208M -79M -199M -184M -248M -367M -1 348M -415M -223M
link Link Link Link Link
finalLink Link Link Link Link
filingDate 2023-02-28 2022-02-28 2021-02-25 2020-02-26 2019-02-28
fiscalYear 2022 2021 2020 2019 2018
accountsReceivables 0 0 0 0 0
otherReceivables 865 000 0 0 2M 768 000
prepaids 0 0 0 0 0
totalPayables 39M 35M 18M 48M 26M
otherPayables 0 0 0 0 0
accruedExpenses 0 0 0 0 0
capitalLeaseObligationsCurrent 0 0 0 0 0
capitalLeaseObligationsNonCurrent 0 0 0 0 0
treasuryStock 0 0 0 0 0
additionalPaidInCapital 0 0 0 0 0
otherTotalStockholdersEquity 3 453M 3 100M 2 481M 1 145M 751M

Cash Flow Statement

Property 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4 2019 q4 2018 q4
date 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31 2019-12-31 2018-12-31
symbol MRTX MRTX MRTX MRTX MRTX MRTX MRTX MRTX MRTX
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2023-11-06 2023-08-08 2023-05-09 2022-11-08
acceptedDate 2023-11-06 07:08:36 2023-08-08 16:02:56 2023-05-09 16:22:07 2023-02-28 16:26:14 2022-11-08 16:32:24 2022-02-28 16:20:36 2021-02-25 16:37:11 2020-02-26 16:14:04 2019-02-28 16:53:44
calendarYear 2023 2023 2023 2022
period Q3 Q2 Q1 FY Q3 FY FY FY FY
netIncome -162M -177M -185M -741M -174M -582M -358M -213M -98M
depreciationAndAmortization 1M 1M 1M 3M 716 000 2M 641 000 249 000 175 000
deferredIncomeTax -122M -144M 0 0 0 0 -5M 0 0
stockBasedCompensation 45M 39M 47M 186M 43M 114M 86M 56M 16M
changeInWorkingCapital -23M 12M -49M -10M 2M 66M 16M 13M 14M
accountsReceivables -4M -4M -5M -865 000 0 0 0 0 0
inventory -12M -5M -829 000 -3M 0 0 0 0 0
accountsPayables 0 0 -35M -5M 0 71M 23M 23M 13M
otherWorkingCapital -7M 21M 41M -1M 0 -5M -7M -10M 693 000
otherNonCashItems 117M 138M -5M -9M -10M 12M -11M -3M -1M
netCashProvidedByOperatingActivities -144M -131M -190M -571M -138M -389M -272M -148M -70M
investmentsInPropertyPlantAndEquipment -36 000 -722 000 -269 000 -5M -1M -10M -4M -2M -122 000
acquisitionsNet 62M -16M 0 -231M 0 579M 135M 175M 0
purchasesOfInvestments -342M -237M -127M -957M -378M -1 423M -663M -530M -256M
salesMaturitiesOfInvestments 280M 253M 322M 1 187M 393M 844M 527M 356M 110M
otherInvestingActivites -62M 16M 0 0
netCashUsedForInvestingActivites -62M 16M 195M 14M
debtRepayment 0 0 0 0
commonStockIssued 329M 3M 2M 0
commonStockRepurchased 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0
otherFinancingActivites 335M 4M 0 157M
netCashUsedProvidedByFinancingActivities 335M 4M 2M 157M
effectOfForexChangesOnCash 59 000 -34 000 -31 000 0 0 0 0 0 0
netChangeInCash 129M -112M 7M -178M 33M -472M 839M 14M -75M
cashAtEndOfPeriod 259M 130M 243M 236M 299M 414M 886M 47M 33M
cashAtBeginningOfPeriod 130M 243M 236M 414M 266M 886M 47M 33M 108M
operatingCashFlow -144M -131M -190M -571M -138M -389M -272M -148M -70M
capitalExpenditure -36 000 -722 000 -269 000 -5M -1M -10M -4M -2M -122 000
freeCashFlow -144M -132M -190M -575M -139M -399M -276M -149M -70M
link Link Link Link Link
finalLink Link Link Link Link
filingDate 2023-02-28 2022-02-28 2021-02-25 2020-02-26 2019-02-28
fiscalYear 2022 2021 2020 2019 2018
otherInvestingActivities 231M -579M -135M -175M -146M
netCashProvidedByInvestingActivities 226M -589M -140M -176M -146M
netDebtIssuance 0 0 0 0 0
longTermNetDebtIssuance 0 0 0 0 0
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 0 0 0 0 0
netCommonStockIssuance 0 0 0 0 0
commonStockIssuance 155M 475M 1 204M 328M 131M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 167M 505M 1 251M 338M 141M
netCashProvidedByFinancingActivities 167M 505M 1 251M 338M 141M
incomeTaxesPaid 0 0 0 0 0
interestPaid 0 0 0 0 0

Earning call transcript

2023 q2
2023-08-08 ET (fiscal 2023 q2)
2023 q1
2023-05-09 ET (fiscal 2023 q1)
2022 q4
2023-02-28 ET (fiscal 2022 q4)
2022 q3
2022-11-08 ET (fiscal 2022 q3)
2022 q2
2022-08-03 ET (fiscal 2022 q2)
2022 q1
2022-05-04 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 8
2023-11-06 08:05 ET
Mirati Therapeutics reported for 2023 q3
SEC form 10
2023-11-06 07:08 ET
Mirati Therapeutics reported for 2023 q3
SEC form 10
2023-11-06 00:00 ET
Mirati Therapeutics reported for 2023 q3
SEC form 6
2023-08-09 16:40 ET
Mirati Therapeutics published news for 2023 q2
SEC form 10
2023-08-08 16:02 ET
Mirati Therapeutics reported for 2023 q2
SEC form 6
2023-08-08 16:01 ET
Mirati Therapeutics reported for 2023 q2
SEC form 8
2023-08-08 00:00 ET
Mirati Therapeutics reported for 2023 q2
SEC form 10
2023-08-08 00:00 ET
Mirati Therapeutics reported for 2023 q2
SEC form 6
2023-07-21 06:05 ET
Mirati Therapeutics published news for 2023 q2
SEC form 6
2023-06-23 17:16 ET
Mirati Therapeutics published news for 2023 q1
SEC form 6
2023-06-23 16:02 ET
Mirati Therapeutics published news for 2023 q1
SEC form 8
2023-05-09 00:00 ET
Mirati Therapeutics reported for 2023 q1
SEC form 10
2023-05-09 00:00 ET
Mirati Therapeutics reported for 2023 q1
SEC form 10
2023-02-28 16:26 ET
Mirati Therapeutics reported for 2022 q4
SEC form 6
2023-02-28 16:08 ET
Mirati Therapeutics reported for 2022 q4
SEC form 10
2023-02-28 00:00 ET
Mirati Therapeutics reported for 2022 q4
SEC form 8
2023-02-28 00:00 ET
Mirati Therapeutics reported for 2022 q4
SEC form 6
2023-01-24 16:20 ET
Mirati Therapeutics published news for 2022 q4
SEC form 6
2023-01-24 16:19 ET
Mirati Therapeutics published news for 2022 q4
SEC form 6
2023-01-24 16:17 ET
Mirati Therapeutics published news for 2022 q4
SEC form 6
2023-01-24 16:03 ET
Mirati Therapeutics published news for 2022 q4
SEC form 6
2023-01-24 16:00 ET
Mirati Therapeutics published news for 2022 q4
SEC form 6
2023-01-24 16:00 ET
Mirati Therapeutics published news for 2022 q4
SEC form 6
2023-01-24 16:00 ET
Mirati Therapeutics published news for 2022 q4
SEC form 6
2023-01-24 16:00 ET
Mirati Therapeutics published news for 2022 q4
SEC form 6
2023-01-20 09:20 ET
Mirati Therapeutics published news for 2022 q4
SEC form 6
2023-01-09 13:06 ET
Mirati Therapeutics published news for 2022 q4
SEC form 8
2023-01-09 00:00 ET
Mirati Therapeutics published news for 2022 q4
SEC form 6
2022-12-21 21:20 ET
Mirati Therapeutics published news for 2022 q3
SEC form 6
2022-12-21 21:20 ET
Mirati Therapeutics published news for 2022 q3
SEC form 6
2022-12-12 20:22 ET
Mirati Therapeutics published news for 2022 q3
SEC form 6
2022-12-05 19:00 ET
Mirati Therapeutics published news for 2022 q3
SEC form 6
2022-12-05 17:00 ET
Mirati Therapeutics published news for 2022 q3
SEC form 6
2022-12-02 08:01 ET
Mirati Therapeutics published news for 2022 q3
SEC form 6
2022-11-28 19:01 ET
Mirati Therapeutics published news for 2022 q3
SEC form 6
2022-11-08 18:00 ET
Mirati Therapeutics published news for 2022 q3
SEC form 10
2022-11-08 16:32 ET
Mirati Therapeutics reported for 2022 q3
SEC form 6
2022-11-08 16:23 ET
Mirati Therapeutics published news for 2022 q3
SEC form 10
2022-11-08 00:00 ET
Mirati Therapeutics reported for 2022 q3
SEC form 8
2022-11-08 00:00 ET
Mirati Therapeutics reported for 2022 q3
SEC form 6
2022-09-08 06:08 ET
Mirati Therapeutics published news for 2022 q2
SEC form 10
2022-08-03 16:07 ET
Mirati Therapeutics reported for 2022 q2
SEC form 6
2022-08-03 16:04 ET
Mirati Therapeutics published news for 2022 q2
SEC form 8
2022-08-03 00:00 ET
Mirati Therapeutics reported for 2022 q2
SEC form 10
2022-08-03 00:00 ET
Mirati Therapeutics reported for 2022 q2
SEC form 6
2022-06-14 16:35 ET
Mirati Therapeutics published news for 2022 q1
SEC form 6
2022-06-07 08:06 ET
Mirati Therapeutics published news for 2022 q1
SEC form 6
2022-06-06 08:07 ET
Mirati Therapeutics published news for 2022 q1
SEC form 6
2022-05-26 17:06 ET
Mirati Therapeutics published news for 2022 q1
SEC form 6
2022-05-16 17:01 ET
Mirati Therapeutics published news for 2022 q1
SEC form 6
2022-05-16 16:42 ET
Mirati Therapeutics published news for 2022 q1
SEC form 6
2022-05-12 17:07 ET
Mirati Therapeutics published news for 2022 q1
SEC form 10
2022-05-04 16:22 ET
Mirati Therapeutics reported for 2022 q1
SEC form 6
2022-05-04 16:10 ET
Mirati Therapeutics reported for 2022 q1
SEC form 10
2022-05-04 00:00 ET
Mirati Therapeutics reported for 2022 q1
SEC form 8
2022-05-04 00:00 ET
Mirati Therapeutics reported for 2022 q1
SEC form 6
2022-04-15 16:26 ET
Mirati Therapeutics published news for 2022 q1
SEC form 10
2022-02-28 16:20 ET
Mirati Therapeutics published news for 2021 q4
SEC form 6
2022-02-28 16:06 ET
Mirati Therapeutics published news for 2021 q4
SEC form 10
2022-02-28 00:00 ET
Mirati Therapeutics published news for 2021 q4
SEC form 8
2022-02-28 00:00 ET
Mirati Therapeutics published news for 2021 q4
SEC form 6
2022-02-15 16:16 ET
Mirati Therapeutics published news for 2021 q4
SEC form 6
2022-01-10 10:55 ET
Mirati Therapeutics published news for 2021 q4
SEC form 6
2021-11-12 06:16 ET
Mirati Therapeutics published news for 2021 q3
SEC form 6
2021-11-09 16:24 ET
Mirati Therapeutics published news for 2021 q3
SEC form 10
2021-11-08 16:25 ET
Mirati Therapeutics published news for 2021 q3
SEC form 6
2021-11-08 16:08 ET
Mirati Therapeutics published news for 2021 q3
SEC form 10
2021-11-08 00:00 ET
Mirati Therapeutics published news for 2021 q3
SEC form 8
2021-11-08 00:00 ET
Mirati Therapeutics published news for 2021 q3
SEC form 6
2021-11-01 07:32 ET
Mirati Therapeutics published news for 2021 q3
SEC form 6
2021-09-24 17:10 ET
Mirati Therapeutics published news for 2021 q2
SEC form 6
2021-09-20 08:10 ET
Mirati Therapeutics published news for 2021 q2
SEC form 10
2021-08-05 16:42 ET
Mirati Therapeutics published news for 2021 q2
SEC form 6
2021-08-05 16:34 ET
Mirati Therapeutics published news for 2021 q2
SEC form 10
2021-08-05 00:00 ET
Mirati Therapeutics published news for 2021 q2
SEC form 8
2021-08-05 00:00 ET
Mirati Therapeutics published news for 2021 q2
SEC form 6
2021-07-02 16:04 ET
Mirati Therapeutics published news for 2021 q2
SEC form 6
2021-06-28 17:02 ET
Mirati Therapeutics published news for 2021 q1
SEC form 6
2021-06-01 08:41 ET
Mirati Therapeutics published news for 2021 q1
SEC form 6
2021-05-12 16:21 ET
Mirati Therapeutics published news for 2021 q1
SEC form 10
2021-05-06 16:37 ET
Mirati Therapeutics published news for 2021 q1
SEC form 6
2021-05-06 16:28 ET
Mirati Therapeutics published news for 2021 q1
SEC form 10
2021-05-06 00:00 ET
Mirati Therapeutics published news for 2021 q1
SEC form 8
2021-05-06 00:00 ET
Mirati Therapeutics published news for 2021 q1
SEC form 6
2021-04-16 16:26 ET
Mirati Therapeutics published news for 2021 q1
SEC form 6
2021-03-30 17:41 ET
Mirati Therapeutics published news for 2020 q4
SEC form 6
2021-03-30 17:09 ET
Mirati Therapeutics published news for 2020 q4
SEC form 10
2021-02-25 16:37 ET
Mirati Therapeutics published news for 2020 q4
SEC form 6
2021-02-25 16:31 ET
Mirati Therapeutics published news for 2020 q4
SEC form 6
2021-01-11 07:31 ET
Mirati Therapeutics published news for 2020 q4
SEC form 6
2021-01-08 19:57 ET
Mirati Therapeutics published news for 2020 q4
SEC form 10
2020-11-04 16:47 ET
Mirati Therapeutics published news for 2020 q3
SEC form 6
2020-11-04 16:36 ET
Mirati Therapeutics published news for 2020 q3
SEC form 6
2020-10-28 16:38 ET
Mirati Therapeutics published news for 2020 q3
SEC form 6
2020-10-26 16:53 ET
Mirati Therapeutics published news for 2020 q3
SEC form 6
2020-10-26 08:00 ET
Mirati Therapeutics published news for 2020 q3